RESUMEN
Insulinotropic peptide agents are regarded as potential candidates for anti-diabetic treatment. In the present study, a novel insulinotropic peptide, termed OA-A1, was purified from frog skin secretions of Odorrana andersonii. Mature OA-A1 was determined to be a 1965.049 Da peptide with an amino acid sequence of LVGKLLKGAVGDVCGLLPIC, in which an intramolecular disulfide bridge was formed by two cysteine residues. At the cellular level, OA-A1 exhibited potent proliferation promoting effects on mouse-derived pancreatic ß-TC-6 cells and significantly stimulated insulin release in ß-TC-6 cells at a minimum concentration of 1 nM. In the animal model, OA-A1 also showed a dose-dependent insulin-releasing role in mice. At concentrations ranging from 1 nmol/kg to 1 µmol/kg, OA-A1 had a significant acute hypoglycemic effect on streptozotocin (STZ)-induced diabetic mice. The pancreatic islet areas of diabetic mice increased dose-dependently after 21 days of OA-A1 treatment (1-100 nmol/kg) compared with those of the saline control group. Moreover, OA-A1 significantly improved the oral glucose tolerance of STZ-induced diabetic mice. Taken together, these results suggest that OA-A1 provides an excellent template for the development of novel anti-diabetic therapeutic agents. Copyright © 2017 European Peptide Society and John Wiley & Sons, Ltd.
Asunto(s)
Péptidos/metabolismo , Piel/metabolismo , Animales , Anuros , Proliferación Celular/efectos de los fármacos , Diabetes Mellitus Experimental/tratamiento farmacológico , Prueba de Tolerancia a la Glucosa , Hemólisis/efectos de los fármacos , Hipoglucemiantes/metabolismo , Hipoglucemiantes/uso terapéutico , Masculino , Ratones , Páncreas/efectos de los fármacos , Páncreas/metabolismo , Estreptozocina/toxicidadRESUMEN
Objective: Preventive effect of hippocampal sparing on cognitive dysfunction of patients undergoing whole-brain radiotherapy and imaging assessment of hippocampal volume changes. Methods: Forty patients with brain metastases who attended Liaoning Cancer Hospital from January 2018 to December 2019 were identified as research subjects and were randomly divided into a control group and an experimental group, with 20 cases in each group. The control group was treated with whole-brain radiotherapy (WBRT), and the experimental group was treated with hippocampal sparing-WBRT (HS-WBRT). The Montreal Cognitive Assessment (MoCA) score, Eastern Cooperative Oncology Group (ECOG) score, cancer quality-of-life questionnaire (QLQ-C3O) score, hippocampal volume changes, and prognosis of the two groups were compared. Results: The MoCA scores decreased in both groups at 3, 6, and 12 months after radiotherapy, with significantly higher scores in the experimental group than in the control group (P < 0.05). After radiotherapy, both groups had lower ECOG scores, with those in the experimental group being significantly lower than those in the control group (P < 0.05). After radiotherapy, the QLQ-C30 score was elevated in both groups, and that of the experimental group was significantly higher than that of the control group (P < 0.05). The experimental group outperformed the control group in terms of the prognosis (P < 0.05). The hippocampal volume of the control group was significantly smaller than that of the experimental group (P < 0.05). Conclusion: The application of hippocampal sparing in patients receiving whole-brain radiotherapy is effective in preventing cognitive dysfunction, improving the quality of life and prognosis of patients, and avoiding shrinkage of hippocampal volume.